[Federal Register Volume 69, Number 73 (Thursday, April 15, 2004)]
[Notices]
[Page 20023]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-8493]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Therapeutic Administration of the Scrambled Anti-Angiogenic Peptide 
C16Y

K.E. Csaky (NEI), M.L. Ponce (NEI), H. Kleinman (NIDCR)
PCT Application No. PCT/US04/04142 filed 12 Feb 2004 (DHHS Reference 
No. E-008-2004/0-PCT-01)
Licensing Contact: Susan Rucker; 301/435-4478; [email protected].

    This application relates to the field of anti-angiogenesis. In 
particular, the application describes and claims compositions and 
methods useful for treating diseases associated with angiogenesis such 
as macular degeneration (AMD), diabetic retinopathy, neovascular 
glaucoma and cancers associated with solid tumors particularly, breast 
cancer. The compositions and methods offer alternatives to other ocular 
anti-angiogenic agents currently in development due to their ease of 
manufacture and mode of action on an integrin pathway.
    The compositions and methods utilize a synthetic peptide of between 
8 and 12 amino acid residues derived from a region of the [gamma]1 
chain of laminin-1 that binds to endothelial cell integrins 
[alpha]v[beta]3 and [alpha]5[beta]1. The preferred embodiment, 
designated C16Y, is 12 amino acids in length and is easily prepared by 
conventional peptide synthesis. The anti-angiogenic properties of the 
C16Y peptide have been demonstrated in an in vitro model of choroidal 
neovascularization and in tumor-bearing mice.
    This work has been published, in part at ML Ponce et al., Cancer 
Research 63(16): 5060 (Aug 15, 2003).

Hybrid Adeno-Retroviral Vector for the Transformation of Cells

Changyu Zheng, Brian C. O'Connell, Bruce J. Baum (NIDCR)
U.S. Provisional Application No. 60/179,327 filed 31 Jan 2000 (DHHS 
Reference No. E-258-1998/0-US-01); PCT Application No. PCT/US01/03026 
filed 30 Jan 2001 (DHHS Reference No. E-258-1998/0-PCT-02); U.S. Patent 
Application No. 10/182,644 filed 30 Jul 2002 (DHHS Reference No. E-258-
1998/0-US-03)
Licensing Contact: Jesse Kindra; 301/435-5559; [email protected].

    The invention described and claimed in this patent application 
provides for novel hybrid vectors which may be used for cell 
transformation, either in vivo or in vitro. The hybrid vectors have an 
adenoviral backbone with retroviral long terminal repeats (LTRs). Such 
vectors are capable of transforming dividing or non-dividing cells and 
integrate stably into the chromosome providing a means of efficient, 
reliable, long-term gene expression. The vector was packaged as a 
recombinant adenovirus and delivered to the target cell. Unlike other 
chimeric or hybrid vector systems, only a single vector is required to 
deliver a transgene of interest, and retroviral structural proteins are 
not required.
    This work has been published, in part, in: Zheng et al., Nature 
Biotechnol. (2000 Feb) 18(2):176-180; Zheng et al., Biochem. Biophys. 
Res. Commun. (2002 Feb 15) 291(1):34-40; Zheng et al., Biochem. 
Biophys. Res. Commun. (2003 Jan 3) 300(1):115-20; Zheng et al., 
Virology (2003 Sep 1) 313(2):460-72.

Antitumor Macrocyclic Lactones

Michael R. Boyd (NCI)
U.S. Patent No. 6,353,019 issued 05 Mar 2002 (DHHS Reference No. E-244-
1997/0-US-07) and related foreign patent applications; and

Vacuolar-Type (H+)-ATPase-Inhibiting Compounds and Uses Thereof

Michael R. Boyd (NCI)
U.S. Patent Application No. 09/914,708 filed 31 Aug 2001 (DHHS 
Reference No. E-244-1997/3-US-06) and related foreign patent 
applications
Licensing Contact: George Pipia; 301/435-5560; [email protected].

    This technology covers a broad composition of matter which includes 
the salicylihalamides, lobatamides, and numerous other structurally 
related small molecules which have been shown to inhibit mammalian 
vacuolar ATPase at low nanomolar concentrations. The compounds are also 
potent inhibitors of cancer cell growth, with particular specificity 
for melanoma, osteosarcoma and selected lung, colon and CNS tumor cell 
lines. Experimental tumor and pharmacokinetic studies are underway to 
select the most effective analogs for further development. The 
potential of these compounds to inhibit invasion and metastasis to bone 
sites is also under investigation.

    Dated: April 7, 2004.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 04-8493 Filed 4-14-04; 8:45 am]
BILLING CODE 4140-01-P